Department of Neurosurgery, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
Cancer Immunol Immunother. 2013 Jan;62(1):75-86. doi: 10.1007/s00262-012-1312-7. Epub 2012 Jul 1.
Th17 cells, a recently discovered inflammatory T cell subtype, have been implicated with autoimmune disorders. However, mechanism of generation or functions of intratumoral Th17 cells are still unclear. We have been investigating the mechanism of induction and role of Th17 cells in malignant gliomas using primary tumor as well as cell lines. We report here that: (1) a higher frequency of Th17 cells in gliomas were associated with higher number of myeloid (CD11b) cells as well as the expression of TGF-β1 or IL-6; (2) conditioned medium from glioma cells (Gl CM) induced Th17 cell differentiation, which was inhibited by anti-TGF-β1 and anti-IL-6; (3) glioma-associated monocytes secreted Th17-promoting cytokines IL-1β and IL-23; (4) CM from glioma and monocyte co-culture (Gl+Mo CM) induced high frequency of Th17 cells in naïve T cell culture, which was abrogated by anti-IL-1β and anti-IL-23 antibodies; (5) In vitro Gl+Mo CM-mediated Th17 generation was associated with a decrease in IFN-γ and a concomitant increase in IL-10 secretion. Anti-TGF-β1, but not anti-IL-6, significantly reversed this cytokine profile. These results demonstrate prevalence of Th17 cells in gliomas and implicate the cytokines derived from the tumor as well as infiltrating myeloid cells in the induction of Th17 cells in glioma microenvironment. Moreover, the data also suggest that glioma-associated Th17 cells may contribute to immune-suppression via TGF-β1-induced IL-10 secretion. Further studies on the mechanism of tumor-infiltration, developmental pathways, and pro-/anti-tumor functions of Th17 cells will provide rationale for developing novel adjuvant immunotherapeutic strategies for malignant gliomas.
Th17 细胞是一种新近发现的炎症性 T 细胞亚群,与自身免疫性疾病有关。然而,肿瘤内 Th17 细胞的产生机制或功能仍不清楚。我们一直在使用原发性肿瘤和细胞系研究 Th17 细胞在恶性神经胶质瘤中的诱导机制和作用。我们在此报告:(1)Th17 细胞在神经胶质瘤中的频率较高与髓样细胞(CD11b)的数量以及 TGF-β1 或 IL-6 的表达有关;(2)来自神经胶质瘤细胞的条件培养基(Gl CM)诱导 Th17 细胞分化,该分化被抗 TGF-β1 和抗 IL-6 抑制;(3)神经胶质瘤相关单核细胞分泌促进 Th17 细胞的细胞因子 IL-1β 和 IL-23;(4)神经胶质瘤和单核细胞共培养的 CM(Gl+Mo CM)在未成熟 T 细胞培养物中诱导 Th17 细胞的高频率,该频率被抗 IL-1β 和抗 IL-23 抗体阻断;(5)体外 Gl+Mo CM 介导的 Th17 生成与 IFN-γ 的减少和 IL-10 分泌的增加有关。抗 TGF-β1,但不是抗 IL-6,可显著逆转这种细胞因子谱。这些结果表明 Th17 细胞在神经胶质瘤中普遍存在,并提示肿瘤来源的细胞因子以及浸润的髓样细胞在胶质瘤微环境中诱导 Th17 细胞。此外,数据还表明,神经胶质瘤相关的 Th17 细胞可能通过 TGF-β1 诱导的 IL-10 分泌来促进免疫抑制。进一步研究肿瘤浸润、发育途径以及 Th17 细胞的促/抗肿瘤功能,将为开发治疗恶性神经胶质瘤的新型辅助免疫治疗策略提供依据。